SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: BCYP) is a clinical-stage biopharmaceutical company that reached the public markets through its merger with Big Cypress Acquisition Corp, a healthcare-focused blank-check company that completed its IPO in 2021. Big Cypress was sponsored by Big Cypress Holdings LLC and targeted opportunities in the life sciences and biotechnology sector. SAB Biotherapeutics develops fully human polyclonal antibody therapeutics using a proprietary genetically engineered cattle platform. The company filed an 8-K with the SEC on July 21, 2025, bearing accession number 0000950170-25-097078. Sign up at SpacDesk for full filing history, sponsor data, and real-time alerts on BCYP and hundreds of other SPAC-linked issuers.